Trial Profile
An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Ivosidenib (Primary)
- Indications Cholangiocarcinoma
- Focus Adverse reactions; Registrational
- Acronyms ProvIDHe
- Sponsors Servier
- 29 May 2023 New trial record